Bcg

• BCG is a live attenuated bacterial strain derived from Mycobacterium bovis.
• It is primarily known globally as a vaccine to prevent tuberculosis, particularly severe forms in children.
• BCG also serves as an effective immunotherapy for non-muscle-invasive bladder cancer.
• While generally safe, the BCG vaccine can cause local side effects and, rarely, more severe reactions.
• Its efficacy against tuberculosis varies, offering better protection against severe childhood forms than against adult pulmonary disease.

What is BCG (Bacillus Calmette-Guérin)?

Bacillus Calmette-Guérin (BCG) is a vaccine and a form of immunotherapy derived from an attenuated strain of Mycobacterium bovis, a bacterium closely related to the one that causes tuberculosis in humans. Developed by Albert Calmette and Camille Guérin in the early 20th century, BCG has a long history of medical use. It functions by stimulating the body’s immune system, making it effective in two distinct medical applications.

As a vaccine, BCG is primarily used to protect against tuberculosis (TB), a serious infectious disease caused by Mycobacterium tuberculosis. The World Health Organization (WHO) recommends BCG vaccination for all infants in countries with a high incidence of TB, as it provides significant protection against severe forms of childhood TB, such as tuberculous meningitis and disseminated TB.

BCG Vaccine: Efficacy and Side Effects

The efficacy of the BCG vaccine varies depending on geographical location, genetic factors, and the specific strain of BCG used. While it offers good protection against severe forms of TB in children, its effectiveness against pulmonary TB in adults is more variable, ranging from 0% to 80% according to various studies. Despite this variability, the WHO continues to recommend its use in high-burden countries due to its proven benefit in preventing severe childhood disease. For instance, a meta-analysis cited by the WHO indicates that BCG vaccination reduces the risk of TB meningitis and disseminated TB in children by 70-80%.

Common BCG vaccine side effects are generally mild and localized. These typically include:

• Redness, swelling, and tenderness at the injection site.
• A small sore or ulcer that may develop, often healing with a characteristic scar.
• Swelling of lymph nodes in the armpit (axillary lymphadenopathy).

More severe side effects are rare but can occur, especially in individuals with compromised immune systems. These may include disseminated BCG infection, osteitis (bone infection), or extensive local reactions. Healthcare providers carefully assess a patient’s health status before administering the vaccine to minimize risks.

BCG Treatment for Bladder Cancer

Beyond its role as a vaccine, BCG treatment for bladder cancer is a well-established and effective immunotherapy, particularly for non-muscle-invasive bladder cancer (NMIBC). Administered directly into the bladder via a catheter, BCG stimulates a localized immune response. The immune cells are activated to recognize and destroy cancer cells lining the bladder, preventing recurrence and progression of the disease.

This intravesical therapy is considered the most effective adjuvant treatment for high-risk NMIBC following transurethral resection of bladder tumor (TURBT). Studies have shown that BCG significantly reduces the risk of tumor recurrence and progression compared to chemotherapy or observation alone. While effective, this treatment can cause side effects such as bladder irritation, frequent urination, blood in the urine, and flu-like symptoms, which are generally manageable.